Long-term safety and efficacy of rimabotulinumtoxinB in the treatment of adult sialorrhea
Objective: To assess the safety, tolerability and effectiveness of repeated rimabotulinumtoxinB injections in adults with troublesome sialorrhea over a period of 1 year. Background: Sialorrhea…RimbotulinumtoxinB in the treatment of adult sialorrhea
Objective: To assess efficacy, safety and tolerability of repeat injections of rimabotulinumtoxinBfor the treatment of sialorrhea. Background: Sialorrhea (drooling) can cause significant morbidity in several neurological disorders,…Duration of rimabotulinumtoxinB action in the treatment of adult sialorrhea
Objective: To assess the duration of rimabotulinumtoxinB action in the management of sialorrhea. Background: In neurological disorders, sialorrhea (drooling) is both prevalent and problematic. Local…GLYCOPAR – A randomized, placebo-controlled, 2-arm parallel-group superiority phase II study of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease
Objective: To assess the 3-month efficacy and safety of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease. Background: A systematic review reported that sialorrhea affects approximately…Parotitis as Adverse Event Following BoNT Injections for Sialorrhea
Objective: Review potential adverse events of parotitis with botulinum toxin injections for sialorrhea. Background: Sialorrhea is a common non-motor symptom of Parkinson’s disease. Botulinum toxin…Atropine as Alternate Therapy for Treatment of Sialorrhea in Parksinson’s Disease
Objective: Evaluating effectiveness of sublingual Atropine 1% ophthalmic solution for treatment of sialorrhea in Parkinson’s disease. Background: Sialorrhea is common non-motor symptom of Parkinson’s disease.…Correlation Between Drooling and Quality of Life in Parkinson’s Disease
Objective: The aim of this study was to evaluate the relationship between the quality of life and drooling in Parkinson’s disease patients. Background: Parkinson’s disease…Effects of Botulinum Toxin treatment for sialorrhea in patients with cerebral palsy
Objective: To evaluate the benefits of treatment of drooling with Botulinum Toxin Type A (AbobotulinumtoxinA) in patients with cerebral palsy. Background: Patients with cerebral palsy…Efficacy of incobotulinumtoxinA in patients with sialorrhea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson’s disease (mROMP): Results of the SIAXI study
Objective: The pivotal double-blind, randomised Phase III SIAXI study (NCT02091739), assessed the efficacy and safety of incobotulinumtoxinA 75 or 100 U for sialorrhea. Co-primary endpoints…Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhea in Parkinson’s disease and other neurologic conditions
Objective: SIAXI (NCT02091739), a pivotal double-blind, randomised, placebo-controlled study with a 48-week extension period (EP), assessed the efficacy and safety of incobotulinumtoxinA 75 U or…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.